Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review

Janković, Slobodan M.; Tesic, Danka; Anđelković, Jelena; Kostić, Marina

doi:10.1080/14737167.2018.1501679

Cited by 2 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gene expression can be measured with transcriptomics, which reads cRNA, processed from mRNA, and is useful for assessing relationships between regulatory elements and phenotypes ( 58 ). For example, PCSK9 mRNA was degraded with a single dose of RNA interfering Inclisiran, reducing LDL-C by 57% for 240 days in phase II trials ( 59 , 60 ) which may be a cheaper alternative to evolocumab ( 61 ).…”

Section: Resultsmentioning

confidence: 99%

Panomics: New Databases for Advancing Cardiology

Vakili

Radenković²,

Chawla

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

The multifactorial nature of cardiology makes it challenging to separate noisy signals from confounders and real markers or drivers of disease. Panomics, the combination of various omic methods, provides the deepest insights into the underlying biological mechanisms to develop tools for personalized medicine under a systems biology approach. Questions remain about current findings and anticipated developments of omics. Here, we search for omic databases, investigate the types of data they provide, and give some examples of panomic applications in health care. We identified 104 omic databases, of which 72 met the inclusion criteria: genomic and clinical measurements on a subset of the database population plus one or more omic datasets. Of those, 65 were methylomic, 59 transcriptomic, 41 proteomic, 42 metabolomic, and 22 microbiomic databases. Larger database sample sizes and longer follow-up are often better suited for panomic analyses due to statistical power calculations. They are often more complete, which is important when dealing with large biological variability. Thus, the UK BioBank rises as the most comprehensive panomic resource, at present, but certain study designs may benefit from other databases.

show abstract

Section: Resultsmentioning

confidence: 99%

Panomics: New Databases for Advancing Cardiology

Vakili

Radenković²,

Chawla

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…L’efficacia delle statine nel ridurre il livello di LDL-C risulta spesso incompiuta, a causa della mancata aderenza al trattamento, fattore che contribuisce a interrompere la terapia ( 60 , 61 ).…”

Section: Discussioneunclassified

“…La non aderenza a seguito della terapia con le statine risulta indotta da molteplici fattori, tra cui i più rilevanti risultano essere caratterizzati dalle preoccupazioni circa gli eventi avversi associati al farmaco, l’intolleranza alle statine e la presenza di insufficienza cardiaca e di emodialisi renale ( 60 ). Gli inibitori del PCSK9 rappresentano una nuova opportunità per i pazienti per i quali il livello di LDL-C non risulta adeguatamente controllato mediante la terapia con statine alla dose massimamente tollerata.…”

Section: Discussioneunclassified

“…Una recente revisione pubblicata nel 2018 che aveva tra gli obiettivi quello di valutare anche il rapporto costo-efficacia di evolocumab in pazienti adulti ad alto rischio cardiovascolare in diversi Paesi europei e negli Stati Uniti ha fatto emergere come le stime di ICER emerse nelle analisi effettuate nei vari Paesi europei risultino un po’ borderline rispetto alle soglie di disponibilità a pagare stabilite in ciascun Paese ( 60 ).…”

Section: Discussioneunclassified

See 1 more Smart Citation

Cost-utility analysis of evolocumab in patients with ASCVD in Italy

Marcellusi

Bini

Rotundo

et al. 2021

Grhta

View full text Add to dashboard Cite

Objective: The aim of this work was to evaluate the cost-effectiveness of evolocumab in addition to standard statin therapy with or without ezetimibe in the treatment of patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) with levels of LDL-C above 100 mg/dL. Method: A theoretical cohort of patients was forecast by a Markov model that includes 11 health states for a lifetime horizon. In the base-case, the standard therapy was characterized by statins with or without ezetimibe. Two sub-populations have been considered, Recent MI (Myocardial Infarction in the last year) and Multiple events (population with multiple MI). The results were also presented for a subset of the Multiple events populations consisting of patients who have experienced a myocardial infarction (MI) in the last year. Results: For the Recent MI and Multiple events populations, ICER values of € 39,547 and € 35,744 respectively were estimated. The value of ICER was lower for the Multiple events with MI < 1 year population (€ 29,949). Considering statins with ezetimibe as standard therapy, ICER values were found to be equal to € 39,781, € 35,986 and € 30,190 respectively for the populations Recent MI, Multiple events and Multiple events with MI < 1 year. Conclusions: The estimated ICER values for the Recent MI, Multiple events and Multiple events populations with MI < 1 year were below the cost-effectiveness threshold of € 40,000, suggesting therefore how the treatment with evolocumab in addition to the standard therapy can be a cost-effective treatment both compared to standard therapy with statins and standard therapy with statins + ezetimibe.

show abstract

Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review

Cited by 2 publications

References 46 publications

Panomics: New Databases for Advancing Cardiology

Panomics: New Databases for Advancing Cardiology

Cost-utility analysis of evolocumab in patients with ASCVD in Italy

Contact Info

Product

Resources

About